New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - influenza virus haemagglutinin type a/vietnam/1194/2004 nibrg-14 (h5n1) 3.75ug - suspension for injection - 3.75 mcg - active: influenza virus haemagglutinin type a/vietnam/1194/2004 nibrg-14 (h5n1) 3.75ug excipient: dibasic sodium phosphate dodecahydrate magnesium chloride monobasic potassium phosphate octoxinol polysorbate 80 potassium chloride sodium chloride thiomersal water for injection d-alpha tocoferol dibasic sodium phosphate dodecahydrate monobasic potassium phosphate polysorbate 80 potassium chloride sodium chloride squalene water for injection - indicated for prophylaxis of influenza in an officially declared pandemic situation. the vaccine may only be marketed, or distributed in accordance with the directives contained in the current version of the new zealand influenza pandemic action plan.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - vi capsular polysaccharide of s. typhi ty2 25ug;   - solution for injection - 25 mcg/0.5ml - active: vi capsular polysaccharide of s. typhi ty2 25ug   excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenol sodium chloride water for injection - active immunisation against typhoid fever for adults and children older than two years of age.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid - injection - min 30 iu/0.5 ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid (d) - injection - min 30iu/0.5ml

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - rotavirus vaccine 1e+006 ccid50 (rix4414 strain, grown in vero cells) - powder with diluent for oral suspension - 1e+006 ccid50 - active: rotavirus vaccine 1e+006 ccid50 (rix4414 strain, grown in vero cells) excipient: amino acids dextran 40 dulbecco's modified eagle medium sorbitol sucrose calcium carbonate water for injection xanthan gum - rotarix is indicated for the prevention of rotavirus gastroenteritis

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml (virus antigen (hm175 strain)); vi capsular polysaccharide of s. typhi ty2 25 µg/ml;   - suspension for injection - active: hepatitis a vaccine 1440 eu/ml (virus antigen (hm175 strain)) vi capsular polysaccharide of s. typhi ty2 25 µg/ml   excipient: aluminium hydroxide amino acids formaldehyde neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - hepatyrix is indicated for active immunisation of adults and adolescents older than 15 years of age at risk of both hepatitis a virus infection and typhoid fever. immunisation with hepatyrix is particularly recommended in subjects who are, or will be, at increased risk of infection such as travellers from countries of low endemicity to areas where the prevalence of hepatitis a and typhoid fever is high.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml;  ; hepatitis a vaccine 1440 eu/ml - suspension for injection - 1440 eu/ml - active: hepatitis a vaccine 1440 eu/ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml;  ; hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml - suspension for injection - 720 elisa u/0.5ml - active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - live attenuated human rotavirus 1e+006 ccid50 ((rix 4414 strain)) - oral suspension - 1e+006 ccid50 - active: live attenuated human rotavirus 1e+006 ccid50 ((rix 4414 strain)) excipient: di-sodium adipate dulbecco's modified eagle medium sucrose water for injection - rotarix is indicated for the prevention of rotavirus gastroenteritis

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - varicella vaccine 2000 pfu (not less than); varicella vaccine 2000 pfu (not less than) - powder for injection with diluent - 2000 pfu - active: varicella vaccine 2000 pfu (not less than) excipient: albumin amino acids lactose monohydrate mannitol sorbitol water for injection active: varicella vaccine 2000 pfu (not less than) excipient: amino acids lactose mannitol sorbitol - varilrix is indicated for active immunisation and prophylaxis against varicella in healthy infants (from the age of 9 months), children, adolescents and adults.